Compare Quest Diagnostics Inc (DGX) vs Nasdaq Inc (NDAQ) Price & Performance

Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.

The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.

Nasdaq (NDAQ) trades at $92.37, up 0.48% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $1.07 versus $0.984, and revenue growth from $7.4B in 2024 to $8.3B in 2025. Recent news highlights Nasdaq's AI-powered Calypso platform adoption by HSBC and Moderna joining the Nasdaq-100 Index, signaling business momentum. Valuation metrics include P/E of 26.93 and P/S of 6.07, with analyst consensus price target at $110.43.

NDAQ presents a favorable outlook with consistent earnings beats and strategic AI integration driving growth. Risks include market volatility sensitivity and debt levels, but strong institutional support and bullish analyst ratings suggest upside potential. The stock's current price offers a 19.6% discount to consensus target, making it attractive for growth-oriented investors seeking exposure to financial technology and market infrastructure.